MTOR and exocrine pancreatic carcinoma: Intriguingly, when rapamycin was administered in a model of pancreatic carcinoma, mTOR was involved in the maintenance of stem-like property of pancreatic cancer stem cells and mTOR inhibitor significantly impaired in vivo growth of xenografted pancreatic carcinoma [38].